Evidence map›Paper›PMID 25766618›Full record

ReviewExperimental & molecular medicine2015

Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.

Bhumsoo Kim, Eva L Feldman

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental & molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03363516 (Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL), which is not on this map. Cited by 171 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03363516 unknown statusnot on this mapstarted 2016, after this paper: background citation

Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL

TypeobservationalSponsorMaria PerticoneRan2016 to 2018Enrolled30ConditionsGlucose Metabolism Disorders, Mild Cognitive ImpairmentArmsCerebral 3 Tesla MRI
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bhumsoo KimDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Tissue-Specific Metabolic Reprogramming in Diabetic ComplicationsDP3DK094292 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C, BURANT, CHARLES F · 2011 to 2011
$5.5M
NIDDK NIH HHS 1DP3DK094292NIDDK NIH HHS DP3 DK094292NIDDK NIH HHS P30 DK020572PHS HHS R24 082841
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes obesity, diabetes, and dyslipidemia. Accumulating evidence implies that MetS contributes to the development and progression of Alzheimer's disease (AD); however, the factors connecting this association have not been determined. Insulin resistance (IR) is at the core of MetS and likely represent the key link between MetS and AD. In the central nervous system, insulin plays key roles in learning and memory, and AD patients exhibit impaired insulin signaling that is similar to that observed in MetS. As we face an alarming increase in obesity and T2D in all age groups, understanding the relationship between MetS and AD is vital for the identification of potential therapeutic targets. Recently, several diabetes therapies that enhance insulin signaling are being tested for a potential therapeutic benefit in AD and dementia. In this review, we will discuss MetS as a risk factor for AD, focusing on IR and the recent progress and future directions of insulin-based therapies.

Indexed as

Insulin ResistanceAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainCognition DisordersHumansInsulinMetabolic SyndromeMolecular Targeted TherapySignal Transductiontau ProteinsAmyloid beta-PeptidesInsulintau Proteins

Identifiers

PMID25766618
PMCPMC4351418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.